Yiwei CHUVisting Professor

Tumor immunology and Immunotherapy / Regulatory B cell in autoimmune diseases and tumor.

Dr. Chu received her M.D in Shanghai Medical University, and her PhD in Immunology in Fudan University in China. She was a visiting scholar in University of Washington, Seattle, USA from 1995-1998, and a visiting professor in Earle A Chiles Research Institute, Portland, Oregon, USA in 2003-2004. Dr. Chu started her carrier in China where she distinguished herself through her work on tumor immunology. Her research interesting has two major focuses. The first is tumor immunology and Immunotherapy, followed by a series of successful projects focusing on tumor vaccine for glioma patients and CAR-T designing for solid tumors. The second is to investigate the regulatory functional of B lymphocyte both in autoimmune disease and cancer, which is the emerging field in Immunology. She published 251 scientific papers, which some of them are in top with high impact factors (H-Index 45 with 6830 citations).

Dr.Chu is a supervisory scientists and team leader, she has served in many professional organizations, including IUIS (International Union of Immunology Society) General Assembly Representative, 17th /18thICI (IUIS 2019/2022) scientific program committee member, vice president of both CSI(Chinese Society for Immunology), and SCI(Shanghai Society for Immunology). She is the chairman of Committee for Woman Scientists in CSI. She leads more than 7,000 women membership for academic and teaching in annual meeting and various activities.


Publications/Patents (recent)

Wanwei Zheng, Huan Song, Zhongguang Luo, Hao Wu, Lin Chen, Yuedi Wang Haoshu Cui, Yufei Zhang, Bangting Wang, Wenshuai Li, Yao Liu, Jun Zhang, Yiwei Chu*, Feifei Luo*, Jie Liu*. Acetylcholine ameliorates colitis by promoting IL-10 secretion of monocytic myeloid-derived suppressor cells through the nAChR/ERK pathway. PNAS. 2021 118(11):e2017762118

Qian J, Luo F, Yang J, Liu J, Liu R, Wang L, Wang C, Deng Y, Lu Z, Wang Y, Lu M, Wang JY, Chu Y*.TLR2 Promotes Glioma Immune Evasion by Downregulating MHC Class II Molecules in Microglia. Cancer Immunol Res. 2018 6(10):1220-1233.

Qian J#, Wang C#, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R, Chu Y*.The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018 15(1):290(1-13)

Liu R, Lu Z, Gu J, Liu J, Huang E, Liu X, Wang L, Yang J, Deng Y, Qian J, Luo F, Wang Z, Zhang H, Jiang X, Zhang D, Qian J, Liu G, Zhu H, Qian Y, Liu Z, Chu Y*. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. Gastroenterology. 2018;154(3):637-651

Lu Z, Liu J, Liu X, Huang E, Yang J, Qian J,3, Zhang D, Liu R*, Chu Y*. MiR-15a/16-1 Suppresses AHR-dependent IL-22 Secretion in CD4+ T cells and Contributes to Immune-mediated Organ Injury.Hepatology. 2017 ; 67(3):1027-1040